Back to Search Start Over

Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial

Authors :
Fujisawa, Takao
Shimoda, Terufumi
Masuyama, Keisuke
Okubo, Kimihiro
Honda, Kohei
Okano, Mitsuhiro
Katsunuma, Toshio
Urisu, Atsuo
Kondo, Yasuto
Odajima, Hiroshi
Kurihara, Kazuyuki
Nagata, Makoto
Taniguchi, Masami
Taniuchi, Shoichiro
Doi, Satoru
Matsumoto, Tomoshige
Hashimoto, Shoji
Tanaka, Akihiko
Natsui, Kensuke
Abe, Nahoko
Ozaki, Hideki
Source :
Allergology International; July 2018, Vol. 67 Issue: 3 p347-356, 10p
Publication Year :
2018

Abstract

To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.

Details

Language :
English
ISSN :
13238930 and 14401592
Volume :
67
Issue :
3
Database :
Supplemental Index
Journal :
Allergology International
Publication Type :
Periodical
Accession number :
ejs45737940
Full Text :
https://doi.org/10.1016/j.alit.2017.11.004